Abstract 1572P
Background
The determinants of choices of orientation towards medical oncology have been little explored.
Methods
Medical students of the classes 2022 and 2023 in Lille and Amiens Universities (North of France) were enrolled in a quantitative online survey, with 2 follow-up over 2 months. 36 potential determinants from previous works (Wright et al. 2004; Beaulieu et al. 2010) were evaluated using a 5-point Likert scale alongside parameters. Choosing oncology was assessed among 44 specialities. We identified determinants using both CHAID method and binary and multiple linear regressions, and CHAID method.
Results
Responders were 563 (563/1250; 45%). CHAID analysis retained 2 factors: “medical oncology traineeship” (p<.0001) and “identification with a doctor in the specialty” (p=.049). when excluding factors associated with énd-cycle trining, CHAID analysis retained 2 factors associated with a career choice in oncology: “rejection of emergency care” (p=.036) and “wish of hospital-university career” (p=.006). Motivations differed according to sexes. In men, choosing oncology was associated in multivariate analysis with: “hospital traineeship in medical oncology” (β=0.22; p=.010), “hospital traineeship in oncology radiotherapy” (β=0.22; p<0.001) and “interest in fundamental research” (β=0.06; p<.001). Conversely, “rural life” (β=-0.09; p=.014) was negatively associated with this choice. In women, parameters positively associated with choosing oncology were: “hospital traineeship in medical oncology” (β=0.289; p<.001), “long-term relationship with patients” (β=0.12; p=.021) and “hospital work” (β=0.21; p=0<.001). A negative association was observed for: “treatment with visible outcome in the short term” (β=-0.15; p=.018) and “rural life” (β=-0.15; p=.006).
Conclusions
Motivations varied according to sexes. Hospital experience during the second cycle of medical studies plays a determining role. The ability or the interest in emergency management seems important in career choice. Certain interests influence career choice (long-term relationship with patient) as well as contextual factors (rural life). These results can be interpreted according to Bandura's social cognitive theory.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centre Oscar Lambret.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10